Editing Celecoxib (section)

=== Brand names ===
Pfizer markets celecoxib under the brand name Celebrex, and it is available as oral capsules containing 50, 100, 200, or 400&nbsp;mg of celecoxib.<ref name="Celebrex FDA label" />

It is legally available in many jurisdictions as a generic under several brand names.<ref>{{cite web | title=Celecoxib | website=Drugs.com | date=4 May 2020 | url=https://www.drugs.com/international/celecoxib.html | access-date=5 May 2020 | archive-date=10 March 2016 | archive-url=https://web.archive.org/web/20160310184046/http://www.drugs.com/international/celecoxib.html | url-status=live }}</ref> In the US, celecoxib was covered by three patents, two of which expired on 30 May 2014, and one of which (US RE44048<ref>{{cite web |url=https://patents.google.com/patent/USRE44048 |title=US Re-issued Patent RE44048 |access-date=10 November 2016 |archive-date=9 January 2017 |archive-url=https://web.archive.org/web/20170109190350/https://www.google.com/patents/USRE44048 |url-status=live }}</ref>) was due to expire 2 December 2015. On 13 March 2014, that patent was found to be invalid for [[double patenting]].<ref>{{cite web | vauthors = Parloff R | title=Judge cuts 18 months off patent life of Pfizer's Celebrex | website=[[Fortune (magazine)|Fortune]] | date=13 March 2014 | url=https://fortune.com/2014/03/13/judge-cuts-18-months-off-patent-life-of-pfizers-celebrex/ | access-date=5 May 2020 | archive-date=25 July 2017 | archive-url=https://web.archive.org/web/20170725162355/http://fortune.com/2014/03/13/judge-cuts-18-months-off-patent-life-of-pfizers-celebrex/ | url-status=live }}</ref> Upon the patent expiry on 30 May 2014, the FDA approved the first versions of generic celecoxib.<ref>{{cite press release | title=FDA approves first generic versions of celecoxib | website=U.S. [[Food and Drug Administration]] (FDA) | date=31 May 2014 | url=https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm399428.htm | archive-url=https://web.archive.org/web/20140531020104/https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm399428.htm | archive-date=31 May 2014 | url-status=dead | access-date=5 May 2020}}</ref>

In the US, Celebrex is marketed by [[Viatris]] after Upjohn was spun off from Pfizer.<ref>{{cite web | title=Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan | publisher=Pfizer | via=Business Wire | date=16 November 2020 | url=https://www.businesswire.com/news/home/20201116005378/en/ | access-date=17 June 2024}}</ref><ref>{{cite web | title=Celebrex | website=Pfizer | url=https://www.pfizer.com/products/product-detail/celebrex | access-date=17 June 2024}}</ref><ref>{{cite web | title=Brands | website=Viatris | date=16 November 2020 | url=https://www.viatris.com/en/products/brands | access-date=17 June 2024}}</ref>